Kailera Therapeutics, Inc. (KLRA)
| Market Cap | 2.91B |
| Revenue (ttm) | n/a |
| Net Income | -148.96M |
| EPS | -7,819.98 |
| Shares Out | 129.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 314,400 |
| Open | 21.52 |
| Previous Close | 21.47 |
| Day's Range | 21.52 - 23.20 |
| 52-Week Range | 20.87 - 28.23 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 23, 2026 |
About KLRA
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights... [Read more]
News
Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity ca...
Kailera Stock (KLRA) Rockets 68% after IPO in Race for $150B Obesity Market
Kailera Therapeutics’ ($KLRA) shares soared as high as 68% on Friday following its public debut on Nasdaq, with the obesity treatment developer raising $625 million from the initial public offering…
Kailera surges over 60% in Nasdaq debut as weight-loss drug race heats up
Weight-loss drug developer Kailera Therapeutics' shares surged 62.5% in their Nasdaq debut on Friday after closing a $625 million U.S. initial public offering, as Wall Street's appetite for the fast...
Kailera Therapeutics opens at $26, IPO priced at $16 per share
Kailera Therapeutics (KLRA) priced 39.06M shares at $16.00. The deal size was increased and priced at the high end of the range. Kailera is an advanced clinical-stage biotechnology company that…
Kailera Therapeutics indicated to open at $21, IPO priced at $16
Kailera Therapeutics (KLRA) priced 39.06M shares at $16.00. The deal size was increased to 39.06M shares from 33.3M and priced at the high end of the $14.00-$16.00 range. Published first…
Kailera Therapeutics indicated to open at $24, IPO priced at $16
Kailera Therapeutics (KLRA) priced 39.06M shares at $16.00. The deal size was increased to 39.06M shares from 33.3M and priced at the high end of the $14.00-$16.00 range. JPMorgan, Jefferies,…
Kailera Therapeutics 39.06M share IPO priced at $16.00
The deal size was increased to 39.06M shares from 33.3M and priced at high end of $14.00-$16.00 range. JPMorgan, Jefferies, Leerink, TD Cowen and Evercore ISI are acting as joint…
Kailera Therapeutics Announces Pricing of Initial Public Offering
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity ca...
Kailera Therapeutics files for US IPO
Kailera Therapeutics has filed for a U.S. initial public offering, it said in a filing on Friday.
Kailera Therapeutics IPO Registration Document (S-1)
Kailera Therapeutics has filed to go public with an IPO on the NASDAQ